Patil VM, et al. - In this open-label, investigator-initiated, phase 3, randomized trial, researchers intended to confirm the already reported benefits of nimotuzumab added to chemoradiation on outcomes in patients with locally advanced head and neck cancer in a phase 2 study. Either radical radiotherapy (66-70 grays) with concurrent weekly cisplatin (30 mg/m²) (CRT) or the same schedule of CRT with weekly nimotuzumab (200 mg) was randomly 1:1 administered to adult patients with locally advanced head and neck cancer who were suitable for radical chemoradiation. Improved progression-free survival, locoregional control, and disease-free survival were achieved by adding nimotuzumab to concurrent weekly CRT. In patients who are treated with radical-intent CRT, this combination affords a new alternative to a 3-weekly schedule of 100 mg/m² cisplatin.